Curaleaf International Launches Range of Medical Cannabis Products in Germany
WAKEFIELD, Mass.– Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF), a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH has launched its own range of medical cannabis products in Germany, Europe’s largest medical cannabis market. The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THC/CBD formulations in both oil and flower formats, addressing a wide range of patient needs. Germany is Europe’s largest medical cannabis market and is expected to be worth US$2.1 billion by 2021.
Antonio Costanzo, CEO of Curaleaf International, said, “We are very pleased to bring our first medical cannabis products to market in Germany and, with the rapid extension of our product range in 2021, establishing ourselves as a leader in Europe’s largest medical cannabis market. Curaleaf International’s European supply chain, from cultivation to product research and development and EU-GMP manufacturing processes across Europe, means we are able to guarantee a consistency of product and price to clinicians and patients in need of the highest quality medical cannabis.”
Julian Vaterrodt, Managing Director, Adven GmbH, added, “German patients and practitioners are increasingly demanding high-quality, consistent and reliable European natural alternatives to help manage a wide range of complaints. Adven is committed to providing a differentiated product and service for the German market. We focus on providing a consistent supply of high-quality European medical cannabis and cutting-edge digital technologies to improve the patient and healthcare professional experience.”
Forward Looking Statements
This press release contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning Adven GmbH’s (“Adven”), launch of medical cannabis products in Germany. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed September 25, 2020, which is available under the Company’s SEDAR profile at www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
(This information is primarily sourced from Curaleaf. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Bloomios Reports Q1 2023 Revenue Growth of 30% Sequentially and 84% Year-on-Year to $2.75 Million
LOS ANGELES-- Santa Barbara-based Bloomios, Inc., a white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics, and pet products, announced its financial results for the first quarter ended March 31, 2023. The company reported ...
BREAKING: Trulieve Disciplined for Worker Death; Announces Exit from Competitive California & Massachusetts Markets
LOS ANGELES–Trulieve, a prominent cannabis company, has recently found itself embroiled in a distressing incident. In Massachusetts, a tragic workplace accident resulted in the death of one of Trulieve's employees. The company has since faced ...
Minnesota Legalizes Recreational Cannabis, Expanding Market and Tax Revenue
MINNESOTA. - Governor Tim Walz of Minnesota has signed into law a bill legalizing the recreational use of cannabis, making Minnesota the 23rd state in the U.S. to do so. The legislation, known as HF ...